Liza Squires
Research Subjects
Liza Squires has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
316 Study Group
Child Development Center Irvine CA USA
1 shared publication- Ann Catherine Childress
Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA
1 shared publication - John M. Giblin
Clinical Study Centers LLC, Little Rock, AR, USA
1 shared publication - Joseph Gao
Shire, Lexington, MA, USA
1 shared publication - Maria Gasior
Global Clinical Medicine, Shire Development Inc., Wayne, PA, USA
1 shared publication - Matthew Brams
Bayou City Research, Houston, TX 77007, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 6 (1) , 34
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment.
- 1 January 2010
- Published by Springer Nature in Behavioral and Brain Functions
- Vol. 6 (1) , 34
Open AccessRandomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment.
- Open Access
- 9 June 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 17
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder
Lisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 to 12 years of age and in adults. In a previous laboratory school study, LDX demonstrated efficacy 2 hours postdose with duration of efficacy through 12 hours. The current study further characterizes the time course of effect of LDX.
- 9 June 2009
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 3 (1) , 17
Open AccessA 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder
Lisdexamfetamine dimesylate (LDX) is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6 to 12 years of age and in adults. In a previous laboratory school study, LDX demonstrated efficacy 2 hours postdose with duration of efficacy through 12 hours. The current study further characterizes the time course of effect of LDX.